Drug Profile
Research programme: small molecule enzyme inhibitors - OncoTherapy Science
Alternative Names: Methyltransferase SUV39H2 inhibitors - OncoTherapy Science; OTS 193320; OTS-514; OTS-964; T-LAK cell-originated protein kinase inhibitors - OncoTherapy Science; TOPK inhibitors - OncoTherapy ScienceLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer OncoTherapy Science; University of Chicago
- Class Antineoplastics; Small molecules
- Mechanism of Action Methyltransferase inhibitors; PDZ-binding kinase inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in Japan (IV)
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (IV)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (IV, Liposomal)